A synthetic compound (506), 0(1-6) D-glucosamine disaccharide 1,4'-bisphosphate, which is acylated at 2'-amino and 3'-hydroxyl groups with (R)-3-dodecanoyloxytetradecanoyl and (R)-3-tetradecanoyloxytetradecanoyl groups, respectively, and has (R)-3-hydroxytetradecanoyl groups at 2-amino and 3-hydroxyl groups, exhibited full endotoxic activities identical to or sometimes stronger than those of a reference lipid A from an Escherichia coli Re-mutant (strain F515). Endotoxic activities tested include pyrogenicity and leukopenia-inducing activity in rabbits, body weight-decreasing toxicity in normal mice, lethal toxicity in galactosamine-sensitized mice and chicken embryos, and the preparation and provocation of the local Shwartzman reaction in rabbits. 
2'-amino and 3'-hydroxyl groups with (R)-3-dodecanoyloxytetradecanoyl and (R)-3-tetradecanoyloxytetradecanoyl groups, respectively, and has (R)-3-hydroxytetradecanoyl groups at 2-amino and 3-hydroxyl groups, exhibited full endotoxic activities identical to or sometimes stronger than those of a reference lipid A from an Escherichia coli Re-mutant (strain F515). Endotoxic activities tested include pyrogenicity and leukopenia-inducing activity in rabbits, body weight-decreasing toxicity in normal mice, lethal toxicity in galactosamine-sensitized mice and chicken embryos, and the preparation and provocation of the local Shwartzman reaction in rabbits. Compound 406, a synthetic counterpart of a biosynthetic precursor of lipid A molecule, showed by contrast only weak activities in all of the above assay systems except for the lethality in galactosamine-loaded mice. This finding strongly suggests that the presence of acyloxyacyl groups at the C-2' and C-3' positions of the disaccharide backbone is one of the most important determinant structures of the lipid A molecule for exhibition of strong biological activities characteristic of lipopolysaccharide and its lipid A moiety. The activities of the corresponding 4'-monophosphate (compound 504) and 1-monophosphate (505) analogs were considerably less than those of the parent molecule 506 and the reference F515 lipid A. Regarding other biological activities, not only compound 506 but also compounds 504, 505, and 406 showed definite activities, sometimes comparable to those of F515 lipid A and other reference natural products. These are the activation of Tachypleus tridentatus amoebocyte clotting enzyme cascade and human complement via the classical pathway, mitogenic and polyclonal B-cell activation of murine splenocytes, stimulation of peritoneal macrophages in a guinea pig, enhancement of migration of human blood polymorphonuclear leukocytes, and induction of a serum factor that is cytostatic and cytocidal to L-929 cells in Mycobacterium bovis BCG-primed mice. Relative potencies of test synthetic compounds depended on the assay systems and varied from one system to another. Dephospho-compound 503 lacked most of the biological activities that were definitely observed with phosphorylated compounds, probably because of its insolubility. This study demonstrates the successful chemical synthesis of an E. coli-type lipid A. In the preceding papers (15, 24) of this series, we described the biological activities of lipid A analogs that were prepared as synthetic counterparts of the acidic, biosynthetic lipid A precursor (17, 18) . One of them, compound 406 (Fig. 1 and the hydroxyl groups at C-3 and C-3' positions of the disaccharide backbone are (R)-3-hydroxytetradecanoyl in compound 406 and its analogs (403 through 405), while the acyl groups at C-2' and C-3' positions of the backbone of E. coli and Salmonella minnesota lipid A's are (R)-3-acyloxyacyl (double acyl) types (9, 22) .
The purpose of the present paper is to report that further synthetic study has accomplished the task of synthetic lipid A having full endotoxic and related biological properties virtually identical with those of the natural lipid A derived from Re-mutant E. coli F515.
MATERIALS AND METHODS
Animals. ICR, BALB/c, C57BL/6, and C3H/HeN mice were purchased from Charles River Japan, Osaka, Japan. BALB/c nulnu and C3H/HeJ mice were obtained from Clea Japan, Osaka, Japan, and Jackson Laboratory, Bar Harbor, Maine, respectively. Domestic Japanese white rabbits and Hartley albino guinea pigs were supplied by Nihon Rabbit Co., Osaka, Japan.
Test materials. (i) Synthetic E. coli-type lipid A and its analogs. Compounds 504 through 506 (free acid or triethylamine [TEA] salt) and the dephospho-derivative compound 503 were synthesized as described in a separate paper (10) (Fig. 1) . Compound 406, a synthetic counterpart of a biosynthetic lipid A precursor from Salmonella sp. (17) whose immunopharmacological activities were examined in the preceding studies (15, 24) , was prepared as previously described (11) and served as one of the reference compounds.
(ii) Reference natural products. Specimens of reference standard lipid A (TEA salt) and Re-LPS (free acid) were prepared from E. coli F515 (08:K27, Re-mutant) and generously supplied by 0. Luderitz and C. Galanos, Max-PlanckInstitut fur Immunobiologie at Freiburg, Federal Republic of Germany. Another reference product was a commercial LPS of E. coli 055:B5 prepared by a modification of the Westphal method and further purified by chromatography (lot no. 5, product no. 203; List Biological Laboratories, Inc., Campbell, Calif.). This preparation was chosen for its negligible mitogenicity to splenocytes of LPS-nonresponding C3H/HeJ mice, which distinguishes it from several other commercially available preparations of E. coli LPS.
Both synthetic and natural products were dissolved or suspended as homogeneously as possible at 2 mg/ml in 0.1% (vol/vol) TEA aqueous solution. Compounds 506 and 406, as well as the three natural products, were apparently clearly dissolved, compounds 504 and 505 were less soluble and gave a slightly turbid solution, and the dephosphocompound 503 was hardly dissolved but gave a fairly stable suspension. The stock solutions (or a suspension), kept at 4°C, were appropriately diluted with distilled water, physiological saline (saline), or cell culture medium before use for assays except in the following tests. In assays on pyrogenicity and leukopenia-inducing activity in rabbits, toxicity in normal mice, and preparatory and provocative activities for local Shwartzman reaction in rabbits, the above stock solution was diluted with an equal volume of aqueous solution (2 mg/ml) of bovine serum albumin (A-7511; Sigma Chemical Co., St. Louis, Mo.) and then appropriately diluted with saline. The bovine serum albumin solution did not provoke any febrile responses in rabbits at a dose of 31.6 ,ug/kg.
Lethal toxicity on galactosamine-loaded mice. The method of Galanos et al. (5) was followed for tests with galactosamine-loaded mice. In brief, groups of C57BL/6 mice (male, 8 to 10 weeks old) were sensitized by intraperitoneal injection of 16 mg of D-galactosamine hydrochloride (Wako Pure Chemicals, Osaka, Japan) in 0.5 ml of phosphate-buffered saline, followed immediately by intravenous injection in graded doses of test materials in 0.2 ml of distilled water or water alone. The death of mice due to intoxication was observed over a 24-h period.
Body weight-decreasing toxicity in normal mice. Groups of five ICR mice (male, 4 weeks old) were injected intraperitoneally with graded doses of test materials in 0.5 ml of the saline. The mice were allowed to take food and water ad libitum and were weighed before and daily after the injection Pyrogenicity. Pyrogenicity was tested as described in Japanese Pharmacopeia, using Japanese domestic white rabbits (weight, 2 to 2.5 kg) (24) .
Leukopenia-inducing activity. Blood specimens were drawn from domestic Japanese white rabbits (weight, 2 to 2.5 kg) at appropriate intervals from the marginal ear vein with a heparinized disposable syringe before and after intravenous injection of test materials. Blood specimens (20 ,ul) were diluted with 10 ml of the diluent for the blood counter (model CEO310; TOA Medical Electronics Co., Tokyo, Japan), and then 3 drops of Quick Lyser (QL-21; TOA) were added to lyse the erythrocytes. Leukocyte number (cells per cubic millimeter) was determined with a Microcell counter (model CC-130; TOA).
Preparative and provocative activities for Shwartzman reaction. Testing for preparative and provocative activities was carried out with Japanese white rabbits (female, weighing around 3 kg) by the conventional methods (24) .
Assay for immunoadjuvant activity. (i) Mice. The methods described by Sterzi and 1Riha (23) (20) .
(iii) Macrophage spreading. Macrophage spreading was determined by the method described by Tanaka et al. (25) . In brief, the total and spreading macrophages in each well, which were cultured overnight as described above, were counted under an inverted phase-contrast microscope. containing 50 ,uM of cytochrome c (from horse heart, Type VI; Sigma) in HEPES (N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid) buffer at 37°C for 10 min. Ten microliters each of wheat germ agglutinin (4 mg/ml; Sigma) and cytochalasin E (500 ,uag/ml; Sigma) were then added, and the culture plate was incubated at 37°C for 15 min. The incubation was done by using Micro Mixer (MX-4; Sanko Junyaku Co., Tokyo, Japan) to accelerate contact of macrophages with the reagents. All the above incubation was done under 5% CO2 in air. Stimulation of murine splenocytes. (i) Stimulation of thymidine uptake. Splenocytes of BALB/c nulnu (male, 8 weeks old), C3H/HeN (male, 9 weeks old), and C3H/HeJ (male, 9 weeks old) mice were incubated with graded doses of test materials in RPMI 1640 medium (without fetal bovine serum) at 37°C for 24 h and then, after the addition of [3H]thymidine (New England Nuclear Corp.), were further cultivated at 37°C for 24 h under 5% CO2 in air (24) . The stimulatory effect was expressed as a ratio of disintegrations per minute in a test culture to disintegrations per minute in the respective control culture.
(ii) Polyclonal B-cell activation. This was determined as described in a previous paper (16) , except for that 2,4,6-trinitrophenylated (TNP) SRBC were used instead of SRBC as a target. Briefly, splenocytes (6 x 106 cells) of BALB/c mice (male, 8 weeks old) were incubated with appropriate doses of test materials in RPMI 1640 medium supplemented with fetal bovine serum. After the incubation under 5% CO2 in air at 37°C for 3 days, the number of hemolytic PFC against TNP-SRBC was determined in a Cunningham chamber. PBA ability of test materials was expressed as the ratio of PFC count in a test culture to that in the control, i.e., as a stimulation index. All determinations were carried out in hexaplicate cultures.
Enhancement of migration of human PMNL. Details of the procedure for measuring enhancement of migration of human polymorphonuclear leukocytes (PMNL) were described in a previous paper (16) . Briefly, this assay was performed with a multiwell chemotaxis assembly (Neuro Probe, Cabin John, Md.) with human PMNL enriched from heparinized peripheral blood. Determination was made of the number of bA positive result was defined as an increase in rectal temperature of more than 0.6'C. ' The mean temperature increase in all test rabbits, irrespective of positive and negative febrile response, with some exceptions (see footnotes e and g).
Peak I, 1 to 1.5 h; peak II, 2.5 to 4 h. d ND, Not done.
e One of three rabbits showed significant temperature decrease of ca. 1MC.
This rabbit was excluded in calculation of the mean temperature changes.
f Some of the rabbits examined for febrile response were not submitted to circulating blood leukocyte count.
g Two of three rabbits showed a marked temperature decrease of ca. 2'C.
These rabbits were not included in calculation of the mean temperature changes.
not lethal. In the assay with chicken embryos, however, marked differences in lethality between compounds 506 and 406 were noted ( Compounds 504 and 505 were considerably less pyrogenic than 506, and compound 503 did not cause a detectable febrile response at a dose as high as 31.6 ,ug/kg.
The positive febrile responses caused by pyrogenic doses of test synthetic compounds were generally accompanied by a significant decrease in the number of circulating blood leukocytes (leukopenia) as noted in rabbits receiving the reference natural products, though leukopenic response seemed to be slightly less affected than febrile response.
(iv) Preparation and provocation of the local Shwartzman reaction. Intracutaneous injection of compound 506 prepared the rabbit skin to be provoked by:subsequent intravenous administration of S. minnesota R595 Re-LPS (100 ,ug per rabbit; prepared in the laboratory of Kasai) ( Table 4 (Table 6 ). Compounds 506, 504, and 406 exerted powerful activity comparable to those of the three natural products in the Pre Gel test. In the Toxicolor test, a recently developed colorimetric method in which a chromogenic substance (22) was used, the activity of 506 was shown to be stronger than that of 406, which had the same level of activity as F515 lipid A. However, the activity of 505 was about three times less than that of F515 Re-LPS. The activity of 504 was about one-third of that of 506. Compound 505 showed weak activity, and the dephosphoanalog (503) was practically inactive. The activity of O55:B5 LPS was three-fourths of that of E. coli O111:B4 LPS which was used in both Pre Gel and Toxicolor tests as a positive standard.
Other biological activities. (i) Activation of human complement. Compounds 504 through 506 activated the complement cascade in human serum as effectively as did F515 lipid A and Re-LPS (Fig. 3) . There are no substantial differences among the dose-response curves given by the above synthetic and natural compounds. Compound 406 and O55:B5 LPS were considerably less active in complement activation, and 503 was hardly active. We then attempted to assess whether the complement activation by compound 506, F515 lipid A, F515 Re-LPS, and O55:B5 LPS was influenced by blocking the classical pathway by addition of EGTA (10 mM) and MgCI2 (5 mM) to the complement serum. Essentially no activation of complement occurred with any of test compounds (Fig. 4) . This finding indicates that complement activation by compound 506, as well as that by reference natural products including E. coli O55:B5 LPS, proceeds almost exclusively via the classical pathway.
(ii) Stimulation of macrophages. Synthetic compounds 506 and 504 strongly stimulated adherent peritoneal exudate cells (macrophages) of a guinea pig to inhibit thymidine uptake, to increase glucosamine incorporation, and to enhance spreading on a culture plate, as did the three reference natural products (Fig. 5) Stimulatory effects of synthetic lipid A and its analogs on guinea pig peritoneal macrophages were also demonstrated in terms of the enhancement of superoxide anion generation by pretreatment of the cells. Synthetic judgement of extent of stimulation and effective dose indicates that among test synthetic compounds, 506 showed the strongest activity, comparable to that of F515 lipid A and slightly stronger than that of 055:B5 LPS, and that the activity of 504 was slightly higher than that of 505 (Table 7) .
(iii) Mitogenic effects on murine splenocytes. The test synthetic compounds (except 503) significantly increased the uptake of thymidine by splenocytes of BALB/c nulnu mice ( Fig. 6 ), indicating that they were powerful B-cell mitogens, as were the reference natural products. Among synthetic compounds, 406 exerted the highest activity, which was close to that of F515 lipid A but considerably less than the activities of other two natural products. (iv) PBA activity. All synthetic compounds, including the dephospho-compound (503), markedly increased anti-TNP-SRBC hemolytic PFC counts in the spleen of BALB/c mice (Fig. 7) . The activities of compounds 504 through 506 seemed to be stronger than those of compound 406 and F515 lipid A at doses of 1 and 10 ,ug/6 x 106 splenocytes. At a dosage level of 0.1 ,ug, compound 506 showed slightly stronger PBA activity than F515 lipid A or 055:B5 LPS. F515 Re-LPS was the most stimulating among test compounds at this dose level.
(v) Enhancement of PMNL migration. All test synthetic compounds enhanced the migration of PMNL derived from human peripheral blood towards themselves, as did the reference natural products (Fig. 8) . When effective dose and extent of stimulation were considered together, the activity of compound 506 was comparable to those of F515 lipid A and Re-LPS, and stronger than those of compound 406 and 055:B5 LPS.
(vi) Immunoadjuvant activities. Synthetic lipid A and its analogs, except 503 (at a dose of 50 p.g), markedly increased specific anti-SRBC hemolytic PFC counts, either direct or indirect, in the spleens of BALB/c mice that had been immunized by intraperitoneal injection of SRBC and test compounds (Fig. 9 ). There were no significant differences in the extent of stimulation effected by compounds 504 through 506 and compound 406. However, the adjuvant activities of these compounds were weaker than those of F515 lipid A and 055:B5 LPS. A seemingly low potency of F515 ReLPSwas partly due to its high toxicity in the mice, as indicated by the finding that two of five mice died within a few days after the immunization. Intrafootpad injections of compounds 506 and 504 (100 ,ug) with ovalbumin (1 mg per animal) in Freund incomplete adjuvant (Difco) induced distinct DTH to ovalbumin in terms of a definitely positive comeal reaction and a markedly elevated antiovalbumin precipitin antibody level in serum (Fig. 10) . The adjuvant activities of compounds 506 and 504 to increase antibody production were stronger than those of 055:B5 LPS, while a reverse trend was observed in DTHinducing activity. In the present assay, F515 lipid A showed some but not significant activity in both induction of DTH and elevation of antibody level. Compounds 503 and 505 were practically inactive. Compound 406, whose adjuvant activity could not be examined along with the newly synthesized compounds because of its limited availability, showed distinct adjuvant activities comparable to that of 506 in both DTH induction and antibody production (average corneal score, 1.7; serum antibody level [ratio to control], 4.3) in a similar assay described previously (24) .
(vii) Induction of a serum factor cytostatic and cytocidal to L-929 cells in BCG-primed mice. Test compounds, except 503, exhibited the distinct activity to induce a serum factor that exerted cytostatic and cytocidal actions on cultured L-929 cells (a possible tumor necrosis factor [2, 8] ) by intravenous injection in ICR mice which had been primed by BCG inoculation 2 weeks in advance (Table 8 ). When the degree of cytostatic and cytocidal actions and effective dose were considered together, the tumor necrosis factor-inducing activity of compound 506 was slightly lower than those of the three natural products but somewhat higher than that of compound 406. The potency of synthetic compounds decreased from compound 406 to 504 to 505. The dephosphoanalog (503) was completely inactive.
DISCUSSION The present findings demonstrate that we have been able to accomplish the synthesis of a lipid A preparation with biological properties identical to those of a natural lipid A of E. coli F515 (08:K27, Re-mutant).
There are marked differences between compounds 506 and 406 in regard to endotoxic activities such as pyrogenicity and leukopenia-inducing activity, activities to prepare and provoke the local Shwartzman reaction in rabbits, and, though less specific to LPS and lipid A, lethal toxicity on chicken embryos. In contrast, smaller differences were noted between compounds 506 and 406 concerning other biological activities. These include activation of the horseshoe crab amoebocyte lysate clotting enzyme cascade and the lethal toxicity in galactosamine-loaded mice.
The finding that compound 406 exhibited high lethal toxicity in galactosamine-loaded mice, as did compound 506 and F515 lipid A, but was nontoxic in chicken embryos, suggests that the lethal toxicity noted with mice sensitized by loading with galactosamine may not reflect the lethality in normal mice. We wanted to examine the lethal toxicity of synthetic compounds in normal mice but could not do so because of their limited availability. Thus, a comparison was made with toxicity and decrease in body weight of normal mice. In this assay, the difference of toxicity between compounds 506 and 406 was less obvious than in the assay with chicken embryos. In this concentration, recent studies of Baracos et al. (1) and Goldberg et al. (7) reveal that a severe loss of body mass during fever and infections results from extensive protein degradation in skeletal muscle that was strongly stimulated by leukocyte pyrogen (interleukin I) and prostaglandin E2.
It appears that the acyloxyacyl groups which are present in compound 506 but absent in compound 406 play a very important role in exhibiting full endotoxic activities of LPS and lipid A. As described in a separate paper (N. Kasai solubilized in this way. This fact may explain the inactivity of compound 503 in almost all of the assay systems.
It may be pertinent to add some comment on the pathway through which human serum complement was activated by compound 506 and natural reference products. There was controversy or confusion concerning the pathway which bacterial LPS activated. This is due to complex chemical composition and considerable variations among species and even strains in the chemical structures of the molecules. However, it has become apparent that a lipid A portion activates the complement via the classical pathway, while a polysaccharide moiety of LPS activates the alternative pathway of the complement (19) . The present data indicating that the ability of compound 506 to activate human serum complement was almost completely blocked by the presence of EGTA provide additional and conclusive proof that the lipid A portion causes the activation of complement via the classical pathway. The finding that the activation of complement by E. coli 055:B5 LPS was almost completely blocked by addition of EGTA seems to be in conflict with the general view that the activation of the alternative pathway is a property common to LPS from various gram-negative bacteria. This might be associated with the fact that the ability of the LPS preparation used in the present study to activate human serum complement was unexpectedly weak.
Compound 506 exhibited definitely stronger activities than the natural counterpart, F515 lipid A, in some assays, such as those for pyrogenicity, leukopenia-inducing activity, and lethality in galactosamine-loaded mice and the Limulus test. A plausible explanation for this finding would be that the F515 lipid A specimen used in this study as a reference standard is a mixture of 1,4'-bisphosphorylated and 4'-monophosphorylated compounds in approximately equal amounts with other minor components, as analyzed by thin-layer chromatography, and the 1,4'-bisphosphate compound (506) tends to be more potent than the 4'-monophosphate analog (504) in the above assays. However, the above statement on relative potencies of compound 506 and F515 lipid A cannot be applicable to the other activities, for example, the mitogenicity and adjuvant activity in mice.
